Researchers combine a single-probe single cell mass spectrometry technique with a bioinformatics software package to quantify cell subpopulations and prioritize metabolite biomarkers, providing a label-free approach to studying cell heterogeneity and improving understanding of cell metabolism in human diseases and response to therapy.
A team of researchers from the Moffitt Cancer Center in Tampa, Florida, and the University of Oklahoma in Norman, Oklahoma, have developed a new method to quantify cell heterogeneity and subpopulations using single-cell metabolomics. In a recent paper published in Analytical Chemistry, the team combined the Single-probe single cell MS (SCMS) experimental technique with a bioinformatics software package, SinCHet-MS (Single Cell Heterogeneity for Mass Spectrometry), to characterize changes in tumor heterogeneity, quantify cell subpopulations, and prioritize the metabolite biomarkers of each subpopulation (1).
SCMS is a mass spectrometry technique used for analyzing the metabolites in single cells. It involves a single-cell isolation step, followed by micro-extraction and MS analysis using a miniaturized probe. The SCMS approach allows for a high level of sensitivity and specificity, which is particularly useful for studying rare or heterogenous cell populations. It can be combined with bioinformatics tools for quantitative analysis of cell subpopulations and identification of metabolite biomarkers.
As proof-of-principle studies, two melanoma cancer cell lines were used as models. The researchers found that after the treatment of the anticancer drug vemurafenib, a new subpopulation emerged in one of the cell lines, while the proportion of the existing subpopulations was changed in the other cell line. Additionally, metabolites for each subpopulation were identified and prioritized for further investigation. The label-free approach can be applied to quantitatively study cell heterogeneity, prioritize markers for further investigation, and improve the understanding of cell metabolism in human diseases and response to therapy.
The new method addresses a significant challenge in the field of metabolomics, which is the lack of applicable experimental platforms, suitable algorithms, software, and quantitative analyses of cell heterogeneity and subpopulations. The researchers believe that the new approach will provide a better understanding of cell metabolism and its role in human diseases, particularly cancer, and improve the development of new therapies.
The study demonstrates the potential of combining the SCMS experimental technique with a bioinformatics tool to study cell heterogeneity, which is a critical factor in tumor growth, metastasis, and response to therapy. The new method provides a more accurate and comprehensive approach to characterizing cell subpopulations and identifying metabolite biomarkers, which can lead to the development of new diagnostic and therapeutic strategies for cancer patients.
Overall, the development of the SinCHet-MS method represents a significant step forward in the field of metabolomics and provides a valuable tool for researchers studying cell heterogeneity and subpopulations in cancer and other diseases.
(1) Liu, R.; Li, J.; Lan, Y.; Nguyen, T. D.; Chen, Y. A.; Yang, Z. Quantifying Cell Heterogeneity and Subpopulations Using Single Cell Metabolomics. Anal. Chem. 2023. DOI: https://doi.org/10.1021/acs.analchem.2c05245
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.